Juswinder Singh at Celgene to Speak at 7th Protein Kinases Conference – May 30-31, 2012 in Boston Juswinder Singh, Founder & Chief Scientific Officer at Celgene Avilomics Research will give a presentation on “The Resurgence of Covalent Drugs” at the 7th Protein Kinases in Drug Discovery Conference
BigNews.Biz - Apr 23,2012 - Juswinder Singh, Founder & Chief Scientific Officer at Celgene Avilomics Research to give a Presentation on “The Resurgence of Covalent Drugs” at the 7th Protein Kinases in Drug Discovery Conference (May 30-31, 2012 in Boston, MA)
Covalent drugs have proved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project. A new class of covalent drugs termed targeted covalent drugs is showing promise in addressing potency, selectivity and drug resistance issues that are challenging for reversible drugs while minimizing potential safety issues.
The presentation will give a historical success of covalent drugs, an overview of the Avilomics platform to design and assess targeted covalent drugs, give, examples of TCIs against Btk, PI3Kalpha and EGFR, and discuss progress in targeted covalent drugs pre-clinically and clinically.
GTCbio is proud to present our 7th Protein Kinases in Drug Discovery Conference. The top companies and experts in the field of Protein Kinases will come together to discuss the latest discoveries. Companies include ArQule, Avila, Beactica AB, Amgen, Bristol-Myers-Squibb, Eli Lilly, Pfizer, Roche, Merck and more!
Keynote & Featured Speakers Include:
Michael Yaffe, Professor, Biology & Biological Engineering, Massachusetts Institute of Technology
Nathanael Gray, Principal Investigator, Biological Chemistry & Molecular Pharmacology, Dana Farber Cancer Institute
Craig C Mello, Nobel Laureate & Distinguished Professor, Molecular Medicine, University of Massachusetts Medical School; HHMI
George Church, Professor, Genetics; Director, Center for Computational Genetics, Harvard Medical School
Steven Burrill, Chief Executive Officer, Burrill & Company
This conference is part of the Omics Evolution Summit which consists of five other conferences:
2nd Genomic & Proteomic Drug Discovery
2nd Next Generation Sequencing
Genome-wide Partnering and Dealmaking
2nd Epigentics in Drug Discovery
3rd RNAi Research and Development
To view the Program Agenda Click Here. For more information, please visit www.gtcbio.com